Hristina Breshkovska
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hristina Breshkovska has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Andrijana Gjorgjeska
University Clinic for Plastic and Reconstructive Surgery, Ss Cyril and Methodius University of Skopje, Skopje, Republic of North Macedonia
2 shared publications - Hristijan Duma
University Clinic for Eye Diseases. Ss Cyril and Methodius University of Skopje, Skopje, Republic of North Macedonia
2 shared publications - Ivana Dohcheva Karajovanov
University Clinic for Dermatology, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, Republic of North Macedonia
2 shared publications - Silvija Duma
University Clinic of Dermatovenerology, Ss Cyril and Methodius University of Skopje, Skopje, Republic of North Macedonia
2 shared publications - Suzana Nikolovska
University Clinic of Dermatovenerology, Ss Cyril and Methodius University of Skopje, Skopje, Republic of North Macedonia
2 shared publications - Vesna Trajkova
General Hospital “8th September”, Skopje, Republic of North Macedonia
2 shared publications
Latest Publications
- Open Access
- 1 December 2025
- Published by Open Exploration Publishing in Exploration of asthma & allergy
- Vol. 3, 1009101
Clinical and autoimmune characteristics associated with angioedema in patients with chronic spontaneous urticaria
Aim: Angioedema is a common but often underestimated manifestation of chronic spontaneous urticaria (CSU). Its presence may indicate higher disease severity, longer duration, and autoimmune involvement. This study aims to assess the clinical relevance and associations of angioedema in CSU patients with disease severity and duration, treatment response to H1-antihistamines, correlation with autoimmune status, and autologous serum skin test (ASST) positivity. Methods: A prospective study was conducted at the Dermatology Department, General Hospital 8th September, Skopje, North Macedonia, from December 2021 to November 2022, including 230 CSU patients. Disease activity was assessed using the Urticaria Activity Score over 7 days (UAS7), and severity was categorized accordingly. Response to H1-antihistamines was defined as achieving UAS7 < 7 for several months. Angioedema was recorded as a symptom regardless of localization. Autoimmune status was based on autoimmune disease history and/or autoantibody (AAb) detection. The ASST was performed, classifying patients as ASST-positive (ASST⁺) or ASST-negative (ASST⁻). Results: Angioedema was observed in 70% of CSU patients, all with accompanying wheals. It was significantly more common in severe CSU than in moderate (82.02% vs. 65.38%, p = 0.026), mild (82.02% vs. 65.96%, p = 0.036), and well-controlled disease (82.02% vs. 45.45%, p = 0.0004). Patients with a positive autoimmune status more often had angioedema than those with a negative status (75.17% vs. 61.18%, p = 0.025). CSU showed longer duration in patients with angioedema (p = 0.000012), with no association to good antihistamine response (p = 0.55). Conclusions: Angioedema in CSU is associated with higher disease activity, autoimmune status, and prolonged disease duration but not with differences in antihistamine response. Its presence marks a more severe phenotype, emphasizing the need for careful monitoring and individualized management.
- 1 December 2025
- Published by Open Exploration Publishing in Exploration of asthma & allergy
- Vol. 3, 1009101
Open AccessClinical and autoimmune characteristics associated with angioedema in patients with chronic spontaneous urticaria
Aim: Angioedema is a common but often underestimated manifestation of chronic spontaneous urticaria (CSU). Its presence may indicate higher disease severity, longer duration, and autoimmune involvement. This study aims to assess the clinical relevance and associations of angioedema in CSU patients with disease severity and duration, treatment response to H1-antihistamines, correlation with autoimmune status, and autologous serum skin test (ASST) positivity. Methods: A prospective study was conducted at the Dermatology Department, General Hospital 8th September, Skopje, North Macedonia, from December 2021 to November 2022, including 230 CSU patients. Disease activity was assessed using the Urticaria Activity Score over 7 days (UAS7), and severity was categorized accordingly. Response to H1-antihistamines was defined as achieving UAS7 < 7 for several months. Angioedema was recorded as a symptom regardless of localization. Autoimmune status was based on autoimmune disease history and/or autoantibody (AAb) detection. The ASST was performed, classifying patients as ASST-positive (ASST⁺) or ASST-negative (ASST⁻). Results: Angioedema was observed in 70% of CSU patients, all with accompanying wheals. It was significantly more common in severe CSU than in moderate (82.02% vs. 65.38%, p = 0.026), mild (82.02% vs. 65.96%, p = 0.036), and well-controlled disease (82.02% vs. 45.45%, p = 0.0004). Patients with a positive autoimmune status more often had angioedema than those with a negative status (75.17% vs. 61.18%, p = 0.025). CSU showed longer duration in patients with angioedema (p = 0.000012), with no association to good antihistamine response (p = 0.55). Conclusions: Angioedema in CSU is associated with higher disease activity, autoimmune status, and prolonged disease duration but not with differences in antihistamine response. Its presence marks a more severe phenotype, emphasizing the need for careful monitoring and individualized management.
- Open Access
- 1 January 2025
- Published by Centre for Evaluation in Education and Science (CEON/CEES) in SANAMED
- Vol. 20 (2) , 195-200
A challenging "silent depth" clinical scenario in North Macedonia: Unmasking a rare case of amelanotic melanoma with trapezius muscle invasion and metastatic disease
Introduction: Amelanotic melanoma is a subtype of melanoma that exhibits little or no pigment on visual or histological examination. Approximately 1-8% of all melanomas are amelanotic. It can mimic various benign or malignant melanocytic and non-melanocytic skin tumors, thereby presenting a significant diagnostic challenge. Primary amelanotic melanoma with muscle involvement is an extremely rare entity. A review of the literature revealed no series or case reports. Case Report: We present the case of a 62-year-old female patient with primary amelanotic melanoma infiltrating the trapezius muscle. The tumor was excised together with a clinically positive lymph node on the right side of the neck. Computed tomography (CT) angiography of the lungs, abdomen, and pelvis demonstrated bilateral diffuse nodular changes, a mediastinal pretracheal lymph node, and multiple diffuse liver lesions, consistent with secondary deposits. Molecular pathology revealed positivity for the BRAF V600E2/K/R/D mutation, and the patient began first-line targeted therapy with BRAF/MEK inhibition in accordance with protocols for BRAF-positive metastatic melanoma. Three months later, a follow-up CT scan demonstrated complete remission of the previously observed metastatic changes. Conclusion: Primary amelanotic melanoma with muscle involvement is exceptionally rare, with no published series or case reports identified. This case highlights the importance of early detection and treatment in suspected melanoma and underscores the need to consider melanoma in all clinically unclear cases.
- 1 January 2025
- Published by Centre for Evaluation in Education and Science (CEON/CEES) in SANAMED
- Vol. 20 (2) , 195-200
Open AccessA challenging "silent depth" clinical scenario in North Macedonia: Unmasking a rare case of amelanotic melanoma with trapezius muscle invasion and metastatic disease
Introduction: Amelanotic melanoma is a subtype of melanoma that exhibits little or no pigment on visual or histological examination. Approximately 1-8% of all melanomas are amelanotic. It can mimic various benign or malignant melanocytic and non-melanocytic skin tumors, thereby presenting a significant diagnostic challenge. Primary amelanotic melanoma with muscle involvement is an extremely rare entity. A review of the literature revealed no series or case reports. Case Report: We present the case of a 62-year-old female patient with primary amelanotic melanoma infiltrating the trapezius muscle. The tumor was excised together with a clinically positive lymph node on the right side of the neck. Computed tomography (CT) angiography of the lungs, abdomen, and pelvis demonstrated bilateral diffuse nodular changes, a mediastinal pretracheal lymph node, and multiple diffuse liver lesions, consistent with secondary deposits. Molecular pathology revealed positivity for the BRAF V600E2/K/R/D mutation, and the patient began first-line targeted therapy with BRAF/MEK inhibition in accordance with protocols for BRAF-positive metastatic melanoma. Three months later, a follow-up CT scan demonstrated complete remission of the previously observed metastatic changes. Conclusion: Primary amelanotic melanoma with muscle involvement is exceptionally rare, with no published series or case reports identified. This case highlights the importance of early detection and treatment in suspected melanoma and underscores the need to consider melanoma in all clinically unclear cases.
- Open Access
- 12 March 2024
- Published by Scientific Foundation Spiroski (publications) in South East European Journal of Immunology
- Vol. 7, 56-60
Toxic Epidermal Necrolysis: Case Report and Review
BACKGROUND: Stevens–Johnson syndrome and toxic epidermal necrolysis (TEN) are severe mucocutaneous adverse drug reactions primarily caused by drugs. Characterized by fever, prodromal symptoms, and extensive epidermal sloughing with mucous membrane involvement (>90%), they are collectively termed epidermal necrolysis and are considered a disease continuum. CASE PRESENTATION: A 65-year-old man presented with widespread erythema and distinctive target-like lesions, accompanied by ruptured flaccid vesicles on the extremities. Following a 4-week carbamazepine treatment for a previous cerebrovascular insult, hematological analysis revealed abnormalities. A multidisciplinary team, including a neurologist, endocrinologist, and ophthalmologist, prescribed a 3-day course of intravenous immunoglobulin at 0.5 g/kg and an initial dose of 300 mg prednisolone for 3 days, supported by additional therapy. Discharged after 3 weeks, the rash completely resolved within 2 months. CONCLUSION: TEN, a severe mucocutaneous condition with a 30% mortality rate, often results from drug exposure. Swift identification of the causative drug is crucial for optimal outcomes. Treatment primarily includes discontinuing the offending drug and offering supportive care for mucocutaneous lesions. A multidisciplinary approach is vital based on organ system involvement. The effectiveness of pharmacological treatments, such as intravenous immunoglobulin and corticosteroids, is continually under evaluation.
- 12 March 2024
- Published by Scientific Foundation Spiroski (publications) in South East European Journal of Immunology
- Vol. 7, 56-60
Open AccessToxic Epidermal Necrolysis: Case Report and Review
BACKGROUND: Stevens–Johnson syndrome and toxic epidermal necrolysis (TEN) are severe mucocutaneous adverse drug reactions primarily caused by drugs. Characterized by fever, prodromal symptoms, and extensive epidermal sloughing with mucous membrane involvement (>90%), they are collectively termed epidermal necrolysis and are considered a disease continuum. CASE PRESENTATION: A 65-year-old man presented with widespread erythema and distinctive target-like lesions, accompanied by ruptured flaccid vesicles on the extremities. Following a 4-week carbamazepine treatment for a previous cerebrovascular insult, hematological analysis revealed abnormalities. A multidisciplinary team, including a neurologist, endocrinologist, and ophthalmologist, prescribed a 3-day course of intravenous immunoglobulin at 0.5 g/kg and an initial dose of 300 mg prednisolone for 3 days, supported by additional therapy. Discharged after 3 weeks, the rash completely resolved within 2 months. CONCLUSION: TEN, a severe mucocutaneous condition with a 30% mortality rate, often results from drug exposure. Swift identification of the causative drug is crucial for optimal outcomes. Treatment primarily includes discontinuing the offending drug and offering supportive care for mucocutaneous lesions. A multidisciplinary approach is vital based on organ system involvement. The effectiveness of pharmacological treatments, such as intravenous immunoglobulin and corticosteroids, is continually under evaluation.
- Open Access
- 23 January 2024
- Published by Scientific Foundation Spiroski (publications) in South East European Journal of Immunology
- Vol. 7, 7-12
Drug Rash with Eosinophilia and Systemic Symptoms Syndrome: Case Report and Literature Review
BACKGROUND: Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome is a rare, potentially life-threatening, drug-induced hypersensitivity reaction. This condition is characterized by a range of symptoms, including cutaneous reaction, hematologic abnormalities, lymphadenopathy, and potential involvement of internal organs. Most DRESS cases are associated with certain medications such as antiseizure drugs, allopurinol, antibacterial sulfonamides, minocycline, and vancomycin. CASE PRESENTATION: We presented a case of 70-year-old women exhibiting maculopapular rash affecting the face, abdomen, and extremities. She experienced generalized pruritus, along with ulcerative crusty lesions on the mouth and mucopurulent conjunctivitis, all of which had persisted for 1 week. She was recently diagnosed with hyperuricemia and had been undergoing treatment with allopurinol for 4 weeks. During her hospital stay, the rash intensified, and there was a worsening involvement of the mucosa in the oral and ocular area. Allopurinol was promptly discontinued, and the patient was prescribed a daily dose of 100 mg prednisolone, gradually tapering off over a 2-month period. Additionally, the treatment included anticoagulants, antibiotics, local application of mild steroid emulsions, antiseptic, and antifungal therapy for the oral mucosa. Antibiotic solutions and natural tear eye drops were used. Over the 2-month period, the rash completely resolved, and the liver enzymes returned to normal levels. CONCLUSION: DRESS syndrome is an unpredictable drug-induced reaction identified by symptoms such as rash, fever, lymphadenopathy, and potential internal organ involvement. Allopurinol is among the medications associated with this condition, particularly when there is a reduced renal clearance and simultaneous use of thiazide diuretics. Prompt withdrawal of the causative drug is the universally accepted approach to manage drug-induced hypersensitivity reactions. The use of systemic corticosteroids can reduce symptoms of delayed hypersensitivity reactions. However, the absence of randomized controlled trials leaves uncertainty about the necessity of administering steroids, sparking a controversial debate regarding their use in such cases.
- 23 January 2024
- Published by Scientific Foundation Spiroski (publications) in South East European Journal of Immunology
- Vol. 7, 7-12
Open AccessDrug Rash with Eosinophilia and Systemic Symptoms Syndrome: Case Report and Literature Review
BACKGROUND: Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome is a rare, potentially life-threatening, drug-induced hypersensitivity reaction. This condition is characterized by a range of symptoms, including cutaneous reaction, hematologic abnormalities, lymphadenopathy, and potential involvement of internal organs. Most DRESS cases are associated with certain medications such as antiseizure drugs, allopurinol, antibacterial sulfonamides, minocycline, and vancomycin. CASE PRESENTATION: We presented a case of 70-year-old women exhibiting maculopapular rash affecting the face, abdomen, and extremities. She experienced generalized pruritus, along with ulcerative crusty lesions on the mouth and mucopurulent conjunctivitis, all of which had persisted for 1 week. She was recently diagnosed with hyperuricemia and had been undergoing treatment with allopurinol for 4 weeks. During her hospital stay, the rash intensified, and there was a worsening involvement of the mucosa in the oral and ocular area. Allopurinol was promptly discontinued, and the patient was prescribed a daily dose of 100 mg prednisolone, gradually tapering off over a 2-month period. Additionally, the treatment included anticoagulants, antibiotics, local application of mild steroid emulsions, antiseptic, and antifungal therapy for the oral mucosa. Antibiotic solutions and natural tear eye drops were used. Over the 2-month period, the rash completely resolved, and the liver enzymes returned to normal levels. CONCLUSION: DRESS syndrome is an unpredictable drug-induced reaction identified by symptoms such as rash, fever, lymphadenopathy, and potential internal organ involvement. Allopurinol is among the medications associated with this condition, particularly when there is a reduced renal clearance and simultaneous use of thiazide diuretics. Prompt withdrawal of the causative drug is the universally accepted approach to manage drug-induced hypersensitivity reactions. The use of systemic corticosteroids can reduce symptoms of delayed hypersensitivity reactions. However, the absence of randomized controlled trials leaves uncertainty about the necessity of administering steroids, sparking a controversial debate regarding their use in such cases.